AAA_Newrange_Bob Archer - pending
Source: Streetwise Reports (10/6/21)
Related Articles
Merus Shares Rise 37% After Firm Presents Multiclonic Antibodies Clinical Data to Molecular Targets & Cancer Therapeutics Summit
Source: Streetwise Reports (10/07/2021)
Merus NV shares traded higher after the company presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs
Source: Streetwise Reports (10/06/2021)
Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACERᵀᴹ AAV capsids that will be utilized to enhance Pfizer's neurologic and cardiovascular gene therapy programs. Voyager will receive an upfront payment of $30 million and is eligible to receive up to $600 million more plus product sales-based royalties, if all options are exercised and certain milestones are achieved.
Silver Viper Seeks to ID High-Grade Silver at La Virginia in Mexico
Source: Streetwise Reports (10/06/2021)
Silver Viper aims to achieve this at La Virginia via a deep-penetrating geophysical survey of the El Rubi target.
Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients
Source: Streetwise Reports (10/06/2021)
Simultaneously, demand is growing for Reliq Health's iUGO Care software as virtual healthcare delivery increases during the COVID-19 pandemic.
Blue Sky Implements Second Strategy to Advance Uranium District in Argentina
Source: Streetwise Reports (10/06/2021)
With two goals, to identify new mineralized deposits at Amarillo Grande and to expand the resource at the project's Ivana deposit, Blue Sky Uranium is carrying out two concurrent drill programs.
Live-Stream Entertainment Shopping Company OOOOO Seals Deal With TikTok
Source: Streetwise Reports (10/06/2021)
Shopping meets entertainment meets community in the latest form of online commerce, which just received a lift through its partnership with TikTok.
SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK
Source: Streetwise Reports (10/05/2021)
SmileDirectClub Inc. shares traded 15% higher after the company reported that the U.S. Patent & Trademark Office has allowed its new patent for the firm's mobile SmileBus concept whereby its SmileShop on wheels is mobilized to expand access to convenient, affordable oral care in remote areas across the U.S. and the U.K.
Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial
Source: Streetwise Reports (10/04/2021)
Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints and decreased monthly focal seizure frequency by 50% or greater from baseline.
AAA_Meta Materials' Board of Award-Winning Experts Drive Sustainability for the Lux Innovator of the Year Award Winner
Source: Streetwise Reports (10/04/2021)
Nova Scotia-based Meta Materials Inc. today confirmed its acquisition of Nanotech Security Corp. and yesterday announced that META has been selected a Lux Innovator of the Year Award winner as part of the Lux Executive Summit 2021, Putting Sustainability at the Heart of Innovation. META’s winning submission was based on its work to develop a transparent, flexible radio-wave reflection film to improve performance of 5G networks.
Merck and Ridgeback Post Interim Data From Phase 3 Antiviral Drug Trial Showing 50% Reductions in Hospitalizations and Deaths in Mild and Moderate COV
Source: Streetwise Reports (10/03/2021)
Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics, oral antiviral molnupiravir reduced risk of hospitalization or death by 50% versus placebo in patients with mild or moderate COVID-19. Merck plans to submit an Emergency Use Authorization application to the U.S. FDA and if authorized it would make molnupiravir the first approved oral antiviral medicine for COVID-19.
Do you want the latest investment ideas delivered to your inbox? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Recommended Articles
Source: Streetwise Reports (10/07/2021)
Source: Streetwise Reports (10/06/2021)
Silver Viper Seeks to ID High-Grade Silver at La Virginia in Mexico
Source: Streetwise Reports (10/06/2021)
Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients
Source: Streetwise Reports (10/06/2021)
Blue Sky Implements Second Strategy to Advance Uranium District in Argentina
Source: Streetwise Reports (10/06/2021)
Live-Stream Entertainment Shopping Company OOOOO Seals Deal With TikTok
Source: Streetwise Reports (10/06/2021)
SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK
Source: Streetwise Reports (10/05/2021)
Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial
Source: Streetwise Reports (10/04/2021)
Source: Streetwise Reports (10/04/2021)
Source: Streetwise Reports (10/03/2021)